Correlation Between Hemoglobin Glycosylation Index and Nerve Conduction Velocity in Patients with Type 2 Diabetes Mellitus

Zelin Li¹,², Yuan Gao³, Yujiao Jia¹,², Shuchun Chen¹,²,⁴

Objective: This study aimed to investigate the relationship between hemoglobin glycation variation index (HGI) and peripheral nerve conduction velocity (NCV) in patients with type 2 diabetes mellitus (T2DM).

Materials and Methods: This is a cross-sectional study, including 324 patients with T2DM were included in this study. Basic information and blood indicators were collected. The motor conduction velocities (MCV) of the bilateral ulnar nerve, median nerve, and common peroneal nerve, and the sensory conduction velocities (SCV) of the ulnar nerve, median nerve, and superficial peroneal nerve were measured. The patients were divided into two groups according to the NCV: normal nerve conduction group (NCVN group) and abnormal nerve conduction group (NCV A group). When the NCV is less than the specific normal value, the patients were divided into the NCV A group. HGI was calculated as the difference between the measured and predicted values of glycosylated hemoglobin (HbA1c) using the linear relationship between HbA1c level and fasting plasma glucose levels. At last, all study participants were divided into High HGI and Low HGI groups using the median of HGI as the boundary. The study also analyzed the correlation between HGI and NCV.

Results: Compared to the NCVN group, the HGI levels of the NCV A group were higher (P < 0.001). The prevalence of NCV A in the high HGI group was higher than that in the low HGI group (P = 0.004). HGI was negatively correlated with bilateral ulnar nerve MCV, bilateral median nerve MCV, bilateral common peroneal nerve MCV, bilateral median nerve SCV and left superficial peroneal nerve SCV, and the correlation still existed after adjusting for confounding factors.

Conclusion: This study found that HGI is inversely associated with NCV in patients with T2DM, and this correlation is higher between HGI and MCV of peripheral nerve.

Keywords: hemoglobin glycation variation index, peripheral nerve conduction velocity, type 2 diabetes mellitus

Introduction

Type 2 diabetes mellitus (T2DM) is one of the most common metabolic diseases worldwide. The International Diabetes Federation estimated that approximately 425 million people with diabetes worldwide, including 115 million in China.¹ T2DM is a disease caused by the disturbance of carbohydrate metabolism, because of insulin resistance and insufficient insulin secretion, characterized by chronic hyperglycemia. The most common and complex complication of T2DM is diabetic peripheral neuropathy (DN), especially diabetic polyneuropathy (DPN).² Approximately 37–45% of
T2DM patients had DN.\(^3\) Despite its high prevalence, it is often underdiagnosed, with approximately 50% of patients are asymptomatic.\(^4\) DN harms the quality of life and can cause an enormous financial burden. Late diagnosis of DN can lead to significant morbidity in the form of diabetic foot ulceration and amputation and increased mortality.\(^5\) Therefore, it is recommended that all patients should be screened for DN when T2DM is diagnosed.\(^6\) Peripheral nerve conduction velocity (NCV) detection is the most sensitive, accurate and reliable method for diagnosing DN.\(^7\)

Several studies have shown that hyperglycemia, Vitamin D deficiency, diabetes duration, hypertension and hyperlipidemia are all risk factors for DN.\(^8,9\) Among them, poor glycemic control is considered the significant risk factor for DN.\(^10\) Glycosylated hemoglobin (HbA1c) is the gold standard for recent 2–3 months of glycemic control. Nevertheless, recent studies found that HbA1c levels are influenced by blood glucose levels and inter-individual biological differences.\(^11,12\) HbA1c can be affected by many factors, such as age, red blood cell lifespan, anemia, genetic factors, etc.\(^13\) Therefore, the hemoglobin glycosylation index (HGI) is introduced to quantify the individual differences between fasting blood glucose (FBG) and HbA1c.\(^14\) Researches found that high HGI levels are associated with many chronic complications of diabetes, including diabetic retinopathy and diabetic nephropathy, especially cardiovascular disease.\(^13–16\)

To our knowledge, this is the first study to detect the correlation between HGI and NCV in patients with T2DM. The purpose of this study is to investigate whether HGI is an independent factor for NCV. In other words, this study is to investigate whether high HGI is a risk factor for NCV. Early identification of risk factors for NCV, and thus screening for at an early stage.

**Materials and Methods**

**Study Design and Study Population**

The study was conducted at the Department of Endocrinology, Hebei General Hospital, using a cross-sectional method. Participants were recruited between December 2018 and December 2019. This study followed the principles in the Declaration of Helsinki and was approved by the medical ethics committee of Hebei General Hospital (The number of ethics committee: NO.2020207). All patients signed informed consent before enrollment. Inclusion criteria for the study: 1) Patients (aged > 18 years old) comply with the WHO diagnostic criteria for diabetes, 1999. 2) NCV tests were performed.

Exclusion criteria for the study: type 1 diabetes or other specific types of diabetes; pregnant or lactating women; severe physical disease; liver or kidney failure; diabetic foot complications; and diseases affecting nerve conduction velocity such as hereditary, demyelinating or multifocal neuropa-thy, radiculopathy, mononeuritis, and cerebrovascular disease.

**Information and Biomarkers Collection**

All participants completed a questionnaire to collect basic information, including gender, age and duration of disease. Height and weight were measured twice by professional physical examination, and the average value was recorded. Blood samples were collected from the patients after 8 hours of fasting. The study tested all blood indicators in the same laboratory. Total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, urea nitrogen, creatinine, uric acid and FBG were measured by professionals using a fully automatic biochemical analyzer. Vitamin D and HbA1c were measured by the laboratory physician using an electrochemical luminescence method.

**The Measurement of NCV**

NCV was recorded using the Keypoint Myoelectric Evoked Potentiometer (Alpine Biomed ApS; Dantec, Denmark) under standard surface stimulation. During the measurement, the electrode was coated with conductive glue and fixed with tape. NCV was measured on both sides of the limbs. The tests were conducted at room temperature (20–25°C), with a stimulation frequency of 1 Hz, a stimulation pulse width of 0.1 ms, and a sensitivity of 5 mV/lattice. The skin temperature of the patients was measured using an infrared thermal imager and controlled between 33 and 34°C. For the investigation of motor nerves, we selected the bilateral ulnar nerve, median nerve, and common peroneal nerve. We selected the bilateral ulnar nerve, median nerve, and superficial peroneal nerve for the investigation of sensory nerves.

**Hemoglobin Glycation Index**

HGI was calculated using the formula:

\[ \text{HGI} = \text{measured HbA1c value} - \text{predicted HbA1c value} \]

The study adopted linear regression to analyze the correlation between HbA1c and FBG, the HbA1c–FBG regression equation was developed based on data obtained.
from all the study subjects. The predicted HbA1c value was calculated by inserting FBG value into the linear regression equation: Predicted HbA1c level = 0.325 × FBG (mmol/L)+5.724 ($r = 0.592$, $P < 0.001$).

**Participant Groupings**

Our study included two groupings. First, the patients were divided into two groups according to the nerve conduction velocity (NCV) (normal value, the specific normal value is shown in the Table 1): normal nerve conduction group and abnormal nerve conduction group.

Second, the patients were divided into the high HGI group (HGI $\geq$-0.32) and the low HGI group (HGI $<$-0.32).

**Statistical Analysis**

All analyses were conducted using Statistical Product and Service Solutions 25.0 (SPSS 25.0). The study tested the distribution normality using the Kolmogorov–Smirnov test. If the data conformed to the normal distribution, it was presented as mean ± standard deviation and comparisons between groups were made using the Student $t$ test. If the data did not conform to the normal distribution, the data were presented as median (25th–75th interquartile range) and comparisons between groups were made using Mann–Whitney U analysis. The data were expressed as numbers (percentages) for categorical variables, and the chi-square test was used for comparisons between groups. The study conducted Logistic regression analysis to study whether HGI is a risk factor for abnormal peripheral nerve conduction group (NCVA) and adopted Spearman or Pearson correlation analysis to analyze the correlation between HGI and NCV. We investigated the independent correlation between HGI and NCV using multiple linear regression analysis. A $P$-value less than 0.05 was considered statistically significant.

**Results**

**Clinical Characteristics of All Participants**

This study included 324 T2DM patients (231 males and 93 females), and 150 patients (46.30%) constituted abnormal peripheral nerve conduction group (NCVA group). The median age of this study population was 56 years old and the mean duration of disease was 8 years. 162 patients had high HGI values, with a mean HGI level of −0.32 (Table 2).

**Comparison of Basic Parameters Between the NCVN Group and NCVA Group**

The HGI levels were significantly increased for patients in the NCVA group compared to patients in the NCVN group.
Compared to the NCVN group, the patients in the NCV A group had lower vitamin D levels, and had a longer disease duration (P=0.010, P=0.006, respectively). (Table 3).

**Comparison of Basic Parameters Between the High and Low HGI Groups**

The prevalence of NCV A was higher in the high HGI group than in the low HGI group (P=0.004) (Figure 2). The high HGI group had higher HbA1c levels and lower vitamin D levels than the low HGI group (P<0.001, P=0.005, respectively) (Table 4).

**Dichotomous Logistic Regression of Nerve Conduction Velocity and HGI**

The study conducted a Dichotomous logistic regression analysis to analyze the correlation between HGI and NCV. Age, disease duration, diastolic blood pressure, glutamate transaminase, vitamin D level, the use of metformin, the use of insulin and HGI were included in this dichotomous logistic model. The result indicated that HGI was a risk factor for NCV A, where the incidence of NCV A increased 1.338-fold for each unit increase in HGI (P=0.004) (Table 5).

**Correlation Analysis of HGI and NCV in Patients with T2DM**

The correlation analysis revealed that HGI was negatively correlated with the bilateral ulnar nerve motor conduction velocities (MCV), median nerve MCV, common peroneal nerve MCV, bilateral median nerve sensory conduction velocities (SCV), and left superficial peroneal nerve SCV (Table 6).

However, there was no correlation between HGI and bilateral ulnar nerve SCV or right superficial peroneal nerve SCV (Table 6).

**Multivariate Linear Correlation Analysis of NCV and HGI Levels in Patients with T2DM**

For all participants, HGI was negatively correlated with the bilateral ulnar nerve MCV, median nerve MCV, common peroneal nerve MCV, bilateral median nerve SCV and left superficial peroneal nerve SCV.

---

**Table 3 Comparison of Indicators Between the NCVN and NCV A Groups**

| Indicator         | NACN (N=174)          | NCV A (N=150)          | P     |
|-------------------|-----------------------|------------------------|-------|
| Gender            | Male (120, 68.97%)    | Male (93, 62.00%)      | 0.188 |
| Age (years)       | 53.52±11.73           | 54.50 (45.00,62.00)    | <0.001* |
| DM duration (years) | 6.00 (2.00,13.00)   | 10.00 (3.00,16.00)     | 0.006* |
| BMI (kg/m²)       | 26.26 (23.42,28.33)   | 26.31±3.69             | 0.977 |
| DBP (mmHg)        | 82.00 (75.00,91.00)   | 80.00 (72.75,88.00)    | 0.039* |
| SBP (mmHg)        | 13.00 (12.00,14.00)   | 13.85±20.16            | 0.609 |
| ALT (U/L)         | 18.80 (14.43,27.35)   | 17.15 (11.68,24.93)    | 0.018* |
| AST (U/L)         | 18.90 (16.10,23.00)   | 19.20 (15.10,25.50)    | 0.888 |
| TC (mmol/L)       | 4.86±1.13             | 4.67 (3.91,5.54)       | 0.387 |
| TG (mmol/L)       | 1.51 (1.01,2.27)      | 1.46 (1.07,2.25)       | 0.871 |
| LDL-C (mmol/L)    | 2.88 (1.87,3.34)      | 2.78 (1.83,3.47)       | 0.456 |
| HDL-C (mmol/L)    | 1.13 (0.90,1.58)      | 1.01 (0.91,1.92)       | 0.879 |
| Scr (mmol/L)      | 70.85 (64.00,80.40)   | 73.10 (63.48,83.10)    | 0.326 |
| BUN (mmol/L)      | 5.20 (4.50,6.30)      | 5.59 (4.48,6.70)       | 0.088 |
| UA (mmol/L)       | 301.08 (248.13,355.90) | 317.37±94.88         | 0.345 |
| Fbg (mmol/L)      | 7.79 (6.30,10.12)     | 8.80 (6.73,11.90)      | 0.004* |
| Vitamin D (ng/mL) | 16.93 (13.80,21.19)   | 15.28 (12.33,19.74)    | 0.010* |
| HbA1c (%)         | 8.10 (6.80,9.00)      | 8.90 (7.70,10.30)      | <0.001* |
| HGI               | -0.54 (-1.12, 0.49)   | 0.05 (-0.76,1.39)      | <0.001* |

Notes: Data are median (25th–75th interquartile range) and mean ± standard deviation. *Denotes significance at a P value of <0.05.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Fbg, fasting blood glucose; Scr, Serum creatinine; BUN, urea nitrogen; UA, uric acid; HbA1c, glycated hemoglobin; HGI, hemoglobin glycosylation index.
superficial peroneal nerve SCV in the crude model 1 (Table 7), model 2 (adjusted for age, BMI, disease duration, systolic blood pressure, diastolic blood pressure) (Table 8) and model 3 (adjusted for age, BMI, disease duration, systolic blood pressure, diastolic blood pressure, glutamate transaminase, glutathione transaminase) (Table 9).

However, there was no correlation between HGI and bilateral ulnar nerve SCV or right superficial peroneal nerve SCV, regardless of adjusted or non-adjusted confounding factors.

**Discussion**

HGI is another indicator of blood glucose, which reflects an individual’s tendency to glycosylate. Individuals with high HGI levels have higher HbA1c levels than expected. Previous studies mainly focused on the relationship between HGI and cardiovascular complications, diabetic nephropathy, diabetic retinopathy. To our knowledge, this is the first study to investigate the relationship between HGI and NCV in patients with T2DM.

DN is the most common complication of type 2 diabetes, and DPN is the most common type of DN. The occurrence and development of DN can be explained by various etiologies, including increased activity of polyols and hexose channels, oxidative stress, complex inflammatory processes.

**Table 4 Comparison of Indicators Between the High HGI and Low HGI Groups**

|                      | High HGI (N=162) | Low HGI (N=162) | P     |
|----------------------|------------------|-----------------|-------|
| Gender               | Male (98, 60.49%)| Male (115, 70.99%)| 0.047*|
| Age (years)          | 56.00 (47.00,66.00) | 56.52 ±11.58     | 0.790 |
| DM duration (years)  | 8.00 (2.00,14.00)  | 7.50 (3.00,15.00) | 0.641 |
| BMI (Kg/m²)          | 26.20 ±3.60       | 26.03 ±3.55 (28.11) | 0.921 |
| DBP (mmHg)           | 82.00 (74.00,90.00) | 80.00 (73.00,89.00) | 0.533 |
| SBP (mmHg)           | 135.24 ±19.80     | 133.00 (120.00,146.00) | 0.385 |
| ALT (U/L)            | 17.10 (11.90,27.00) | 19.00 (14.40,26.10) | 0.130 |
| AST (U/L)            | 19.35 (14.65,25.55) | 19.10 (16.65,22.95) | 0.898 |
| TC (mmol/L)          | 4.77 (3.97,5.58)   | 4.70 (4.02,5.48)   | 0.806 |
| TG (mmol/L)          | 1.55 (1.07,2.40)   | 1.46 (1.02,2.08)   | 0.363 |
| LDL-C (mmol/L)       | 2.83 (1.16,3.48)   | 2.82 (1.61,3.33)   | 0.973 |
| HDL-C (mmol/L)       | 1.05 (0.91,1.64)   | 1.14 (0.91,1.57)   | 0.584 |
| Scr (mmol/L)         | 70.45 (62.78,81.33) | 73.40 (65.40,82.20) | 0.093 |
| BUN (mmol/L)         | 294.43 (239.28,357.75) | 315.35 (261.93,362.63) | 0.099 |
| UA (mmol/L)          | 12.83 (11.90,13.79) | 12.38 (11.90,13.79) | 0.005* |
| HbA1c (%)            | 9.55 (8.60,10.80)  | 7.33 (6.50,8.30)   | <0.001* |
| Prevalence of NCVA   | NCVA (88, 54.32%)  | NCVA (88, 38.27%)  | 0.004* |

**Notes:** Data are median (25th–75th interquartile range). *Denotes significance at a P value of <0.05.

**Abbreviations:** BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose; Scr, serum creatinine; BUN, urea nitrogen; UA, uric acid; HbA1c, glycated hemoglobin.

**Table 5 Dichotomous Logistic Regression of Risk Factors for Abnormal Peripheral Nerve Conduction Velocity in T2DM Patients**

|                      | B (95% CI) | Std. Error | Wald  | P     |
|----------------------|------------|------------|-------|-------|
| Age                  | 1.036 (1.009,1.063) | 0.013 | 7.088 | 0.008* |
| DM duration          | 1.008 (0.968,1.050) | 0.021 | 0.165 | 0.684 |
| DBP                  | 0.978 (0.957,0.999) | 0.011 | 4.349 | 0.037* |
| ALT                  | 0.994 (0.980,1.008) | 0.007 | 0.278 | 0.394 |
| Vitamin D            | 1.954 (1.931,9.969) | 0.022 | 4.539 | 0.033* |
| The use of metformin | 1.878 (0.505,3.526) | 0.082 | 0.212 | 0.645 |
| The use of insulin   | 1.998 (1.125,3.549) | 0.293 | 5.582 | 0.018* |
| HGI                  | 1.338 (1.097,1.633) | 0.102 | 8.233 | 0.004* |

**Note:** *Denotes significance at a P value of <0.05.

**Abbreviations:** DBP, diastolic blood pressure; ALT, alanine aminotransferase; HGI, hemoglobin glycosylation index.
Table 6 The Correlation of HGI and NCV in Patients with T2DM

| Nerve Conduction Velocities          | HGI       |
|--------------------------------------|-----------|
|                                      | r-value  | P-value |
| Left ulnar nerve MCV                 | −0.203*  | <0.001  |
| Right ulnar nerve MCV                | −0.197*  | <0.001  |
| Left median nerve MCV                | −0.162*  | 0.003   |
| Right median nerve MCV               | −0.159*  | <0.001  |
| Left common peroneal nerve MCV       | −0.197*  | <0.001  |
| Right common peroneal nerve MCV      | −0.204*  | <0.001  |
| Left median nerve SCV                | −0.053   | 0.346   |
| Right median nerve SCV               | −0.019   | 0.741   |
| Left median nerve SCV                | −0.187*  | <0.001  |
| Right median nerve SCV               | −0.154*  | 0.007   |
| Left superficial peroneal nerve SCV  | −0.136*  | 0.022   |
| Right superficial peroneal nerve SCV | −0.113   | 0.054   |

Note: *Denotes significance at a P value of <0.05.
Abbreviations: MCV, motor conduction velocities; SCV, sensory conduction velocities.

Table 7 Correlation of HGI with Different Nerve Conduction Velocities in Patients with T2DM in Model I

| Nerve Conduction Velocities          | B (95% CI) | Std. Error | Beta | t     | P     |
|--------------------------------------|------------|------------|------|-------|-------|
| Left ulnar nerve MCV                 | −0.831 (−1.232, −0.429) | 0.204 | −0.221 | −4.071 | <0.001* |
| Right ulnar nerve MCV                | −0.803 (−1.203, −0.404) | 0.203 | −0.215 | −3.957 | <0.001* |
| Left median nerve MCV                | −0.469 (−0.809, −0.129) | 0.173 | −0.150 | −2.715 | 0.007* |
| Right median nerve MCV               | −0.467 (−0.806, −0.128) | 0.173 | −0.149 | −2.707 | 0.007* |
| Left common peroneal nerve MCV       | −0.591 (−0.929, −0.254) | 0.172 | −0.191 | −3.466 | 0.001* |
| Right common peroneal nerve MCV      | −0.701 (−1.026, −0.376) | 0.165 | −0.232 | −4.243 | <0.001* |
| Left median nerve SCV                | −0.831 (−1.658, 0.232)  | 0.226 | −0.053 | −0.943 | 0.346  |
| Right median nerve SCV               | −0.178 (−0.631, 0.274)  | 0.230 | −0.044 | −0.776 | 0.439  |
| Left median nerve SCV                | −0.905 (−1.454, −0.356) | 0.279 | −0.182 | −3.245 | 0.001* |
| Right median nerve SCV               | −0.740 (−1.333, −0.146) | 0.302 | −0.140 | −2.452 | 0.015* |
| Left superficial peroneal nerve SCV  | −0.489 (−0.948, 0.030)  | 0.233 | −0.124 | −2.097 | 0.037* |
| Right superficial peroneal nerve SCV | −0.414 (−0.927, 0.099)  | 0.261 | 0.093  | −1.587 | 0.114  |

Note: *Denotes significance at a P value of <0.05.
Abbreviations: MCV, motor conduction velocities; SCV, sensory conduction velocities.

endothelial dysfunction, increased advanced glycation end products (AGEs), and vitamin D deficiency. This study found that T2DM patients with high HGI levels were more susceptible to NCV and that HGI levels were independently negatively correlated with NCV. Therefore, we suggest that high HGI levels are a risk factor for DN. Following are some possible mechanisms.

First, HGI was proposed to identify glucose metabolism phenotypes, and patients with high HGI levels have a higher sensitivity to protein glycosylation and higher levels of AGEs in tissues. Previous studies showed that individuals with high HGI levels had higher concentrations of AGEs in many tissues, including the liver and skin. The accumulation of AGEs is an essential mechanism for the development of DN. I. Misur et al found that AGEs can be detected on the axons and myelin sheaths of peripheral nerves in patients with DN and that the level of AGEs was positively correlated with the severity of DN. The significant mechanisms of nerve damage caused by AGEs are cross-link formation and AGEs interaction with AGE receptors. AGEs can form cross-links with proteins such as basement membrane, cell matrix, blood vessel wall components, and mitochondrial electron transport chain-related proteins. This kind of cross-link can affect the protein’s normal structure and function. Moreover, intracellular AGEs can induce DNA and nuclear protein alterations, further affecting protein transport and function. Interaction of AGEs with AGE receptors can alter intracellular signaling, including activation of protein kinase C (PKC) isoforms, induction of oxidative stress, activation of NF-KB
signaling pathway, promotion of pro-inflammatory factor production and free radical release, and this alteration can ultimately lead to inflammation and apoptosis production.\textsuperscript{24,26,27} The combination of these mechanisms results in impaired blood flow to the peripheral nerves and impaired nutritional support.

The second possible mechanism is the high HGI levels can affect vitamin D levels, ultimately affecting NCV. Studies also found that vitamin D deficiency is involved in developing DN,\textsuperscript{28,29} and supplementation of Vitamin D can also improve DN.\textsuperscript{9,30} Previously, one of our studies found that T2DM patients with high HGI levels were more susceptible to vitamin D deficiency and that HGI levels were inversely associated with vitamin D levels.\textsuperscript{31} This study also found that the NCVN group had lower vitamin D levels and a higher prevalence of vitamin D deficiency than the NCVA group. Vitamin D is a potent neurotrophic factor, and it is involved in the formation of neurotransmitters.\textsuperscript{30} In addition, vitamin D can reduce insulin resistance by binding to the vitamin D receptor, and reducing the production of inflammatory factors, etc.\textsuperscript{32,33} Therefore, when vitamin D is deficient, it can diminish neurotrophic support, affect glucose metabolism, and ultimately lead to reduced NCV. Hence, we suggest that high HGI levels can affect NCV by affecting vitamin D levels.

In addition, HGI could reflect hyperglycemic fluctuations, and patients with high HGI levels have higher postprandial blood glucose levels.\textsuperscript{34} Postprandial glucose fluctuation can impair NCV by affecting endothelial

---

**Table 8** Correlation of HGI with Different Nerve Conduction Velocities in Patients with T2DM in Model 2

|                        | B (95% CI)          | Std. Error | Beta | t    | P     |
|------------------------|---------------------|------------|------|------|-------|
| Left ulnar nerve MCV   | −0.812 (−1.220, −0.404) | 0.207   | −0.215 | −3.913 | <0.001* |
| Right ulnar nerve MCV  | −0.758 (−1.157, −0.360) | 0.203   | −0.204 | −3.742 | <0.001* |
| Left median nerve MCV  | −0.479 (−0.810, −0.147) | 0.168   | −0.155 | −2.843 | 0.005* |
| Right median nerve MCV | −0.506 (−0.842, −0.171) | 0.171   | −0.163 | −2.970 | 0.003* |
| Left common peroneal nerve MCV | −0.596 (−0.935, −0.257) | 0.172   | −0.191 | −3.456 | 0.001* |
| Right common peroneal nerve MCV | −0.683 (−1.007, −0.360) | 0.164   | −0.226 | −4.155 | <0.001* |
| Left median nerve SCV  | −0.260 (−0.682, 0.161) | 0.214   | −0.066 | −1.216 | 0.225 |
| Right median nerve SCV | −0.174 (−0.614, 0.265) | 0.223   | −0.044 | −0.781 | 0.435 |
| Left median nerve SCV  | −1.065 (−1.581, −0.549) | 0.262   | −0.216 | −4.059 | <0.001* |
| Right median nerve SCV | −0.923 (−1.484, −0.361) | 0.285   | −0.176 | −3.235 | 0.001* |
| Left superficial peroneal nerve SCV | −0.554 (−1.014, −0.094) | 0.234   | −0.140 | −2.371 | 0.018* |
| Right superficial peroneal nerve SCV | −0.437 (−0.951, 0.077) | 0.261   | −0.098 | −1.672 | 0.096 |

**Note:** *Denotes significance at a P value of <0.05.
Abbreviations: MCV, motor conduction velocities; SCV, sensory conduction velocities.

**Table 9** Correlation of HGI with Different Nerve Conduction Velocities in Patients with T2DM in Model 3

|                        | B (95% CI)          | Std. Error | Beta | t    | P     |
|------------------------|---------------------|------------|------|------|-------|
| Left ulnar nerve MCV   | −0.877 (−1.300, −0.455) | 0.215   | −0.231 | −4.090 | <0.001* |
| Right ulnar nerve MCV  | −0.765 (−1.172, −0.358) | 0.207   | −0.207 | −3.697 | <0.001* |
| Left median nerve MCV  | −0.496 (−0.841, −0.150) | 0.176   | −0.159 | −2.820 | 0.005* |
| Right median nerve MCV | −0.565 (−0.915, −0.215) | 0.178   | −0.180 | −3.179 | 0.002* |
| Left common peroneal nerve MCV | −0.649 (−1.001, −0.297) | 0.179   | −0.207 | −3.626 | <0.001* |
| Right common peroneal nerve MCV | −0.680 (−1.019, −0.340) | 0.172   | −0.221 | −3.944 | <0.001* |
| Left median nerve SCV  | −0.239 (−0.680, 0.201) | 0.224   | −0.060 | −1.070 | 0.286 |
| Right median nerve SCV | −0.235 (−0.691, 0.220) | 0.232   | −0.038 | −1.016 | 0.310 |
| Left median nerve SCV  | −1.060 (−1.593, −0.527) | 0.271   | −0.215 | −3.911 | <0.001* |
| Right median nerve SCV | −0.935 (−1.514, −0.356) | 0.294   | −0.177 | −3.180 | 0.002* |
| Left superficial peroneal nerve SCV | −0.574 (−1.051, −0.097) | 0.242   | −0.144 | −2.369 | 0.019* |
| Right superficial peroneal nerve SCV | −0.454 (−0.987, 0.078) | 0.270   | −0.101 | −1.681 | 0.094 |

**Note:** *Denotes significance at a P value of <0.05.
Abbreviations: MCV, motor conduction velocities; SCV, sensory conduction velocities.
function, increasing the inflammatory response and oxidative stress.\textsuperscript{35} Liu et al found that high HGI levels were associated with higher inflammatory markers,\textsuperscript{36} possibly causing DN.

This study has some limitations. First, the study adopted a cross-sectional method, and it cannot confirm the negative association between NCV and HGI. Second, this is a single-center clinical study. Moreover, there was no correlation between HGI and bilateral ulnar nerve SCV or right superficial peroneal nerve SCV. More extensive clinical and basic studies are required to clarify the specific relationship between HGI and differences in NCVs and the underlying mechanisms.

In conclusion, this study found that HGI was negatively correlated with the NCV, regardless of adjusted or non-adjusted confounding factors. The results indicate that high HGI is a risk factor for NCV in T2DM patients.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. *Nat Rev Dis Prim.* 2019;5(1):42.

2. Fitri A, Sjahrir H, Bachtiar A, Ichwan M, Fitri FI, Rambe AS. Predictive model of diabetic polyneuropathy severity based on Vitamin D level. *Open Access Macedonian J Med Sci.* 2019;7(16):2626–2629. doi:10.3889/oamjms.2019.454

3. Yokoyama H, Tsuij T, Hayashi S, Kabata D, Shintani A. Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: a cross-sectional Japanese study (JJDM S2) using a non-linear model. *J Diabetes Investig.* 2020;11(2):450–457. doi:10.1111/jdi.13117

4. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care.* 2017;40(1):136–154. doi:10.2337/dc16-2042

5. Ponirakis G, Elhadd T, Chinnayani S, et al. Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar. *J Diabetes Investig.* 2021;12(4):592–600. doi:10.1111/jdi.13388

6. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. *J Diabetes Investig.* 2017;8(5):646–655. doi:10.1111/jdi.12650

7. Won JC, Park TS. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. *Endocrinol Metabol. 2016;31(2):230–238. doi:10.3803/EnM.2016.31.2.230

8. Sánchez-Pozos K, Monroy-Escuitia J, Jaimés-Santoyo J, Granados-Silvestre M, Menjivar M, Ortiz-López MG. Risk factors associated with diabetic neuropathy in Mexican patients. *Cir Cir.* 2021;89(2):189–199. doi:10.24875/CIRU.20000243

9. Karonova T, Stepanova A. High-Dose Vitamin D supplementation improves microcirculation and reduces inflammation in diabetic neuropathy patients. *Nutrients.* 2020;12:9.

10. Esteghamati A, Fotouhi A, Faghhi-Kashani S, et al. Non-linear contribution of serum vitamin D to symptomatic diabetic neuropathy: a case-control study. *Diabetes Res Clin Pract.* 2016;111:44–50. doi:10.1016/j.diabres.2015.10.018

11. Chalewa SA, McCarter RJ, Hempe JM. Biological variation and hemoglobin A1c: relevance to diabetes management and complications. *Pediatr Diabetes.* 2013;14(6):391–398. doi:10.1111/pedi.12055

12. Li K, Song WJ, Wu X, et al. Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations. *Endocrine.* 2018;61(3):473–481. doi:10.1007/s12020-018-1641-1

13. Kim W, Go T, Kang DR, Lee EJ, Huh JH. Hemoglobin glycation index is associated with incident chronic kidney disease in subjects with impaired glucose metabolism: a 10-year longitudinal cohort study. *J Diabetes Complications.* 2021;35(1):107760. doi:10.1016/j.jdiacomp.2020.107760

14. van Steen SC, Woodward M, Chalmers J, et al. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: preterax and DiaMicon Modified Release Controlled Evaluation (ADVANCE) trial. *Diabetologia.* 2018;61(4):780–789. doi:10.1007/s00125-017-4539-1

15. McCarter RJ, Hempe JM, Gomez R, Chalewa SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. *Diabetes Care.* 2004;27(6):1259–1264. doi:10.2337/diacare.27.6.1259

16. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. *Diabetes Care.* 2015;38(6):1067–1074. doi:10.2337/dc14-1844

17. Soros AA, Chalewa SA, McCarter RJ, Shepard R, Hempe JM. Hemoglobin glycation index: a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients. *Pediatr Diabetes.* 2010;11(7):455–461. doi:10.1111/j.1399-5448.2009.00630.x

18. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. *Current Drug Targets.* Jan 2008;9(1):14–36. doi:10.2174/138945008783431781

19. Van Dam PS, Cotter MA, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. *Eur J Pharmacol.* 2013;719(1–3):180–186. doi:10.1016/j.ejphar.2013.07.017

20. Jende JME, Groener JB, Okononou D, et al. Diabetic neuropathy differs between type 1 and type 2 diabetes: insights from magnetic resonance neurography. *Ann Neurol.* 2018;83(3):588–598. doi:10.1002/ana.25182

21. Kim MK, Jeong JS, Yun JS, et al. Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: a 10-year longitudinal cohort study. *J Diabetes Complications.* 2018;32(10):906–910. doi:10.1016/j.jdiacomp.2018.08.007

22. Felipe DL, Hempe JM, Liu S, et al. Skin intrinsic fluorescence is associated with hemoglobin A1c and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes. *Diabetes Care.* 2011;34(3):1816–1820. doi:10.2337/dc11-0049

23. Misur I, Zarovič K, Barada L, Butička L, Milicević Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. *Acta Diabetol.* 2004;41(4):158–166. doi:10.1007/s00592-004-0160-0

24. Chillioli NC, Burlina S, Lapolla A. AGES, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view. *Nutri Metabol Cardiovasc Dis.* 2013;23(10):913–919. doi:10.1016/j.numecd.2013.04.004

25. Vincent AM, Calabek B, Roberts L, Feldman EL. Biology of diabetic neuropathy. *Handb Clin Neurol.* 2013;115:591–606.

26. Yeh CH, Sturgis L, Haidacher J, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. *Diabetes.* 2001;50(6):1495–1504. doi:10.2337/diabetes.50.6.1495

27. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. *Circ Res.* 2003;93(12):1159–1169. doi:10.1161/01.RES.0000103862.26506.3D
28. Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes?. *Diabetic Med*. 2012;29(1):43–49.

29. Söderstrom LH, Johnson SP, Diaz VA, Mainous AG 3rd. Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001–2004 NHANES. *Diabetic Med*. 2012;29(1):50–55. doi:10.1111/j.1464-5491.2011.03379.x

30. Ghadiri-Anari A, Mozafari Z, Gholami S, et al. Dose vitamin D suppletions improve peripheral diabetic neuropathy? A before-after clinical trial. *Diabetes Metab Syndr*. 2019;13(1):890–893. doi:10.1016/j.dsx.2018.12.014

31. Li Z, Wang F, Jia Y, Guo F, Chen S. The relationship between hemoglobin glycation variation index and Vitamin D in Type 2 diabetes mellitus. *Diabetes Metabol Syndr Obes*. 2021;14:1937–1948. doi:10.2147/DMSO.S310672

32. Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. *J Endocrinol*. 1999;160(1):87–95. doi:10.1677/joe.0.1600087

33. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. *FASEB J*. 2003;17(3):509–511. doi:10.1096/fj.02-0424fje

34. Riddle MC, Gerstein HC, Hempe, et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. *Diabetes Care* 2015;38:1067-1074. *Diabetes Care*. 2015;38(10):e170–171. doi:10.2337/dc15-1073

35. Pai YW, Lin CH, Lee IT, Chang MH. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. *Diabetes Metab*. 2018;44(2):129–134. doi:10.1016/j.diabet.2018.01.015

36. Liu S, Hempe JM,McCarter RJ, Li S, Fonseca VA. Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. *J Clin Endocrinol Metab*. 2015;100(6):2364–2371. doi:10.1210/jc.2014-4454